Opinion

Video

Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Related Content
Endometrial Cancer | Image Credit: © Crystal light - stock.adobe.com
April 18th 2025

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Pamela T. Soliman, MD, MPH, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center
April 14th 2025

Temsirolimus/Metformin Combo Generates Forward-Looking Questions in Endometrial Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Cadonilimab/Lenvatinib in Endometrial Cancer | Image Credit: © LASZLO - stock.adobe.com
April 8th 2025

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer

Ritu Salani, MD, MBA, gynecologic oncologist, director, Division of Gynecologic Oncology, UCLA Health
April 7th 2025

Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer